Loading…
Metal ions, Alzheimer's disease and chelation therapy
In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegen...
Saved in:
Published in: | Acta pharmaceutica (Zagreb, Croatia) Croatia), 2011-03, Vol.61 (1), p.1-14 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 1 |
container_title | Acta pharmaceutica (Zagreb, Croatia) |
container_volume | 61 |
creator | Budimir, Ana |
description | In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina. |
doi_str_mv | 10.2478/v10007-011-0006-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_863899621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928275231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</originalsourceid><addsrcrecordid>eNpdkE1LAzEQhoMoVqs_wIsseOjF1WTzfSzFWqEiSr30ErKbLN26HzXZFeuvN2VrD57mhXlmmHkAuELwLiFc3H8hCCGPIUJxCCxmR-AMCcJiSak4DhljGDqcDsC592sICeciOQWDBBHIMJZngD7bVpdR0dT-NhqXPytbVNaNfGQKb7W3ka5NlK1sqdvARO3KOr3ZXoCTXJfeXu7rELxPHxaTWTx_eXyajOdxRjht41QiklPJCZc0T2BKoabUaqJzYqSFmSGJSQVmUGc61yQRqTEC0VRwYThiHA_BqN-7cc1nZ32rqsJntix1bZvOK8GwkJIlKJA3_8h107k6HKcQRlJgnHAcKNRTmWu8dzZXG1dU2m0VgmqnVPVKVVCqdkoVCzPX-81dWllzmPhzGIC4Bwrf2u9DX7sPFV7gVL0uiHpD8xleLqeK4F9_9X50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1319833273</pqid></control><display><type>article</type><title>Metal ions, Alzheimer's disease and chelation therapy</title><source>ProQuest - Publicly Available Content Database</source><creator>Budimir, Ana</creator><creatorcontrib>Budimir, Ana</creatorcontrib><description>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</description><identifier>ISSN: 1330-0075</identifier><identifier>EISSN: 1846-9558</identifier><identifier>DOI: 10.2478/v10007-011-0006-6</identifier><identifier>PMID: 21406339</identifier><language>eng</language><publisher>Croatia: Versita</publisher><subject>Alzheimer Disease - drug therapy ; Alzheimer Disease - physiopathology ; Alzheimer's disease ; Alzheimerova bolest ; Animals ; Chelating Agents - pharmacology ; chelation therapy ; Homeostasis - drug effects ; Humans ; Hydroxyquinolines - chemistry ; Hydroxyquinolines - pharmacology ; Ions - metabolism ; kelacijska terapija ; kovinski ioni ; kovinski kelatori ; metal chelators ; metal ions ; Metals - metabolism ; neurodegeneracija ; neurodegeneration ; Neurodegenerative Diseases - drug therapy ; Neurodegenerative Diseases - physiopathology</subject><ispartof>Acta pharmaceutica (Zagreb, Croatia), 2011-03, Vol.61 (1), p.1-14</ispartof><rights>Copyright Versita Mar 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</citedby><cites>FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1319833273?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21406339$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Budimir, Ana</creatorcontrib><title>Metal ions, Alzheimer's disease and chelation therapy</title><title>Acta pharmaceutica (Zagreb, Croatia)</title><addtitle>Acta Pharm</addtitle><description>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</description><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - physiopathology</subject><subject>Alzheimer's disease</subject><subject>Alzheimerova bolest</subject><subject>Animals</subject><subject>Chelating Agents - pharmacology</subject><subject>chelation therapy</subject><subject>Homeostasis - drug effects</subject><subject>Humans</subject><subject>Hydroxyquinolines - chemistry</subject><subject>Hydroxyquinolines - pharmacology</subject><subject>Ions - metabolism</subject><subject>kelacijska terapija</subject><subject>kovinski ioni</subject><subject>kovinski kelatori</subject><subject>metal chelators</subject><subject>metal ions</subject><subject>Metals - metabolism</subject><subject>neurodegeneracija</subject><subject>neurodegeneration</subject><subject>Neurodegenerative Diseases - drug therapy</subject><subject>Neurodegenerative Diseases - physiopathology</subject><issn>1330-0075</issn><issn>1846-9558</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkE1LAzEQhoMoVqs_wIsseOjF1WTzfSzFWqEiSr30ErKbLN26HzXZFeuvN2VrD57mhXlmmHkAuELwLiFc3H8hCCGPIUJxCCxmR-AMCcJiSak4DhljGDqcDsC592sICeciOQWDBBHIMJZngD7bVpdR0dT-NhqXPytbVNaNfGQKb7W3ka5NlK1sqdvARO3KOr3ZXoCTXJfeXu7rELxPHxaTWTx_eXyajOdxRjht41QiklPJCZc0T2BKoabUaqJzYqSFmSGJSQVmUGc61yQRqTEC0VRwYThiHA_BqN-7cc1nZ32rqsJntix1bZvOK8GwkJIlKJA3_8h107k6HKcQRlJgnHAcKNRTmWu8dzZXG1dU2m0VgmqnVPVKVVCqdkoVCzPX-81dWllzmPhzGIC4Bwrf2u9DX7sPFV7gVL0uiHpD8xleLqeK4F9_9X50</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Budimir, Ana</creator><general>Versita</general><general>De Gruyter Poland</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Metal ions, Alzheimer's disease and chelation therapy</title><author>Budimir, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - physiopathology</topic><topic>Alzheimer's disease</topic><topic>Alzheimerova bolest</topic><topic>Animals</topic><topic>Chelating Agents - pharmacology</topic><topic>chelation therapy</topic><topic>Homeostasis - drug effects</topic><topic>Humans</topic><topic>Hydroxyquinolines - chemistry</topic><topic>Hydroxyquinolines - pharmacology</topic><topic>Ions - metabolism</topic><topic>kelacijska terapija</topic><topic>kovinski ioni</topic><topic>kovinski kelatori</topic><topic>metal chelators</topic><topic>metal ions</topic><topic>Metals - metabolism</topic><topic>neurodegeneracija</topic><topic>neurodegeneration</topic><topic>Neurodegenerative Diseases - drug therapy</topic><topic>Neurodegenerative Diseases - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Budimir, Ana</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Acta pharmaceutica (Zagreb, Croatia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Budimir, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metal ions, Alzheimer's disease and chelation therapy</atitle><jtitle>Acta pharmaceutica (Zagreb, Croatia)</jtitle><addtitle>Acta Pharm</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>61</volume><issue>1</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>1330-0075</issn><eissn>1846-9558</eissn><abstract>In the last few years, various studies have been providing evidence that metal ions are critically involved in the pathogenesis of major neurological diseases (Alzheimer, Parkinson). Metal ion chelators have been suggested as potential therapies for diseases involving metal ion imbalance. Neurodegeneration is an excellent target for exploiting the metal chelator approach to therapeutics. In contrast to the direct chelation approach in metal ion overload disorders, in neurodegeneration the goal seems to be a better and subtle modulation of metal ion homeostasis, aimed at restoring ionic balance. Thus, moderate chelators able to coordinate deleterious metals without disturbing metal homeostasis are needed. To date, several chelating agents have been investigated for their potential to treat neurodegeneration, and a series of 8-hydroxyquinoline analogues showed the greatest potential for the treatment of neurodegenerative diseases.
Najnovija istraživanja na polju neurodegeneracije jasno pokazuju da kovinski ioni imaju značajnu ulogu u patogenezi Alzheimerove kao i drugih neurodegenerativnih bolesti. U skladu s ovim spoznajama upotreba kovinskih kelatora predstavlja zanimljiv i inovativan farmakološki pristup daljnjem istraživanju i mogućoj terapiji neurodegenerativnih stanja. U ovom radu ukratko je dan sažetak istraživanja upotrebe kovinskih kelatora u tretmanu Alzheimerove bolesti s posebnim osvrtom na istraživanja analoga 8-hidroksikinolina.</abstract><cop>Croatia</cop><pub>Versita</pub><pmid>21406339</pmid><doi>10.2478/v10007-011-0006-6</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1330-0075 |
ispartof | Acta pharmaceutica (Zagreb, Croatia), 2011-03, Vol.61 (1), p.1-14 |
issn | 1330-0075 1846-9558 |
language | eng |
recordid | cdi_proquest_miscellaneous_863899621 |
source | ProQuest - Publicly Available Content Database |
subjects | Alzheimer Disease - drug therapy Alzheimer Disease - physiopathology Alzheimer's disease Alzheimerova bolest Animals Chelating Agents - pharmacology chelation therapy Homeostasis - drug effects Humans Hydroxyquinolines - chemistry Hydroxyquinolines - pharmacology Ions - metabolism kelacijska terapija kovinski ioni kovinski kelatori metal chelators metal ions Metals - metabolism neurodegeneracija neurodegeneration Neurodegenerative Diseases - drug therapy Neurodegenerative Diseases - physiopathology |
title | Metal ions, Alzheimer's disease and chelation therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A47%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metal%20ions,%20Alzheimer's%20disease%20and%20chelation%20therapy&rft.jtitle=Acta%20pharmaceutica%20(Zagreb,%20Croatia)&rft.au=Budimir,%20Ana&rft.date=2011-03-01&rft.volume=61&rft.issue=1&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=1330-0075&rft.eissn=1846-9558&rft_id=info:doi/10.2478/v10007-011-0006-6&rft_dat=%3Cproquest_cross%3E2928275231%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-b914f5974795f20b50a55ea4af4d9e0cd42db8360acafa428bdd815b878d71673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1319833273&rft_id=info:pmid/21406339&rfr_iscdi=true |